ceftiofur has been researched along with Body-Weight* in 4 studies
1 trial(s) available for ceftiofur and Body-Weight
Article | Year |
---|---|
Safety of ceftiofur sodium administered intramuscularly in horses.
Ceftiofur sodium, a broad-spectrum cephalosporin antibiotic, was evaluated for safe use in horses. Male or female horses were allotted to groups and were given either saline solution (control), or 2.2, 6.6, or 11 mg of an aqueous solution of ceftiofur sodium/kg of body weight/d, IM, for 30 or 31 days. These dosages are expressed in terms of the ceftiofur free acid, and represent 1 to 5 times the proposed therapeutic dosage (2.2 mg/kg/d) administered for 3 times the maximal recommended duration of 10 days. Some of the horses were euthanatized and necropsied on day 31 or 32. The other horses were evaluated for an additional 30 days, and some were euthanatized and necropsied on day 60. The following types of data were collected: clinical observation; physical examination; pelleted food consumption; body weight; hematologic, serum biochemical, and urinalysis findings; organ weight; gross necropsy observations; and histopathologic findings. Ceftiofur sodium was generally well tolerated at the exaggerated doses and treatment durations used in these safety studies. Slight to mild decrease in pelleted food consumption was detected in horses given 6.6 or 11 mg of ceftiofur sodium/kg/d. Decreased food consumption began on day 2 and lasted for approximately 9 to 12 days. Generally, mild skeletal muscle irritation was detected by gross and microscopic examination of the injection sites of horses given ceftiofur sodium. Prevalence and severity of the muscle irritation tended to increase with increasing concentration of the dosing solution.(ABSTRACT TRUNCATED AT 250 WORDS) Topics: Animals; Body Weight; Cephalosporins; Eating; Female; Horse Diseases; Horses; Injections, Intramuscular; Male; Muscular Diseases; Organ Size | 1992 |
3 other study(ies) available for ceftiofur and Body-Weight
Article | Year |
---|---|
Floor eggs: Hatchability, microbiological analysis, and effects of post-hatch use of ceftiofur on performance of broiler chicks.
The present study aimed to determine the effects of egg type (nest clean or floor eggs) on eggshell microbiological, hatching performance, chick quality, yolk sac microbiology, and the interaction between egg type and post-hatch use of ceftiofur on broiler performance at 7, 14, 21, 28 and 35 days. A total of 2500 fertile eggs were obtained from a commercial flock of Cobb Slow® broiler breeders. Half of the eggs were collected directly from the floor, and the other half were collected from the nests. Microbiological evaluation of eggshells was performed before and after sanitization. After hatching, 420 male chicks were randomly selected and distributed in a completely randomized design in a 2 × 2 factorial scheme, separated by the type of egg (clean nest or floor) and the inclusion or not of subcutaneous ceftiofur, totaling four treatments. Egg type did not influence hatchability although the contamination level was 1.3% higher. The body weight and body weight gain of chicks at seven days were greater for chicks from nest eggs that received ceftiofur than chicks from floor eggs that also received ceftiofur. There was no interaction between the studied factors or individual effects for performance at 14, 21, 28, and 35 days. It is concluded that incubation of floor eggs, after standard sanitization, does not influence the hatch results and chick quality. Furthermore, it has been proven that the use of ceftiofur is unnecessary when there is correct management during broiler rearing. Topics: Animals; Body Weight; Chickens; Fertility; Male; Ovum | 2022 |
The contribution of antibiotics, pneumonia and the immune response to stroke outcome.
Infections are common following stroke and associated with worse outcome. Using an animal model of pneumonia, we assessed the effect of infection and its treatment on the immune response and stroke outcome.. Lewis rats were subjected to transient cerebral ischemia and survived for 4weeks. One day after stroke animals were exposed to aerosolized Staphylococcus aureus, Pseudomonas aeruginosa or saline. Antibiotics (ceftiofur or enrofloxacin) were started immediately after exposure or delayed for 3days. Behavioral tests were performed weekly. ELISPOT assays were done on lymphocytes from spleen and brain to assess autoimmune responses to myelin basic protein (MBP).. Among animals that received immediate antibiotic therapy, infection was associated with worse outcome in ceftiofur but not enrofloxacin treated animals. (The outcome with immediate enrofloxacin therapy was so impaired that further worsening may have been difficult to detect.) A delay in antibiotic therapy was associated with better outcomes in both ceftiofur and enrofloxacin treated animals. Infection was associated with an increased likelihood of developing Th1(+) responses to MBP in non-infarcted brain (OR=2.94 [1.07, 8.12]; P=0.04), and Th1(+) responses to MBP in spleen and non-infarcted brain were independently associated with a decreased likelihood of stroke recovery (OR=0.16 [0.05, 0.51; P=0.002 and OR=0.32 [0.12, 0.84]; P=0.02, respectively).. Infection worsens stroke outcome in ceftiofur treated animals and increases Th1 responses to MBP. These data may help explain how infection worsens stroke outcome and suggest that treatment of infection may contribute to this outcome. Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Body Temperature; Body Weight; Cephalosporins; Cytokines; Disease Models, Animal; Enrofloxacin; Fluoroquinolones; Lymphocytes; Male; Myelin Basic Protein; Nervous System Diseases; Pneumonia; Rats; Rats, Inbred Lew; Staphylococcus aureus; Statistics, Nonparametric; Stroke | 2016 |
Experimental infections with Actinobacillus pleuropneumoniae in pigs--I. Comparison of five different parenteral antibiotic treatments.
SPF pigs aged 10 weeks were infected intranasally with Actinobacillus pleuropneumoniae serotype 2. After the onset of clinical symptoms of respiratory disease, which occurred 20 h post-infection, parenteral treatment with ceftiofur, danofloxacin, enrofloxacin, penicillin or tiamulin was initiated (n = 8 per group). Untreated groups, of which one was infected, served as controls. The uninfected control group did not show any signs of disease, while the infected control group was severely affected by the infection and also expressed a decreased weight gain following the challenge. Based on clinical signs, the magnitude of pathological lesions in the respiratory tract found at necropsy performed 17 days post-infection and the number of reisolates of A. pleuropneumoniae made at necropsy, treatments with the quinolones (danofloxacin and enrofloxacin) and the cephalosporine (ceftiofur) were superior to those with penicillin and tiamulin. The latter groups also developed antibodies to A. pleuropneumoniae to a larger extent. Some of the pigs treated with ceftiofur and danofloxacin developed antibodies to A. pleuropneumoniae, and the microbe was reisolated from approximately 50% of these animals. In contrast, pigs treated with enrofloxacin did not develop antibodies to A. pleuropneumoniae, and the challenge strain was not found at necropsy. The performance with respect to daily weight gain and feed conversion corresponded well with the clinical signs developed and the findings made at necropsy. The decreased growth recorded during the acute phase of the disease was, to a large extent, caused by a reduced feed intake. Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Body Weight; Cephalosporins; Diterpenes; Enrofloxacin; Fluoroquinolones; Lung; Lung Diseases; Penicillins; Quinolones; Swine; Swine Diseases; Weight Gain | 1999 |